





# Cetrea GETINGE GROUP

## MONSENSO

#### Jakob E. Bardram

- Professor in Digital Health at DTU Health Tech
  - background in computer science, economics, and psychology
  - University of Aarhus (AU) & University of California at Irvine (UCI)
- Professor at AU and ITU before joining DTU in 2015
- Primary teaching & research areas
  - programming & software architecture (object-oriented)
  - data analysis (AI/ML)
  - medical informatics electronic patient records, clinical logistics, standards
  - mobile health psychiatry, neurology, diabetes, cardiology
- Entrepreneur
  - co-founder of 4 companies e.g., Cetrea A/S and Monsenso A/S



www.bardram.net

## Digital Health at DTU Health Tech

**#1** Biocompatible and flexible electronics for wearable and implantable sensor technology

#2 Biomedical signal processing and health data science

#3 Personalized health technology and digital phenotyping





#### **Outline**

#### **DIGITAL PHENOTYPING**

- Digital Phenotyping
- Digital Biomarkers

#### **COPENHAGEN RESEARCH PLATFORM (CARP)**

- Components
- Data collection | Devices | PRO | Cognition


#### **CASES**

- Psychology
- Psychiatry
- Neurology









## **Digital Phenotyping**

#### Continuous

- 24/7, longitudinal, everywhere

#### Ambulatory

- "in-the-wild", at home, daily life, ...

#### Unobtrusive


- consumer / everyday technology
- mobile & wearable sensing

#### · Large N's


- large-scale deployment
- "cheap" technology

#### Inference & Insights

- behavior, cognition, health, ...
- based on health data science (AI/ML)



- JP Onnela & SL Rauch (2016). Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health. Neuropsychopharmacology. 41(7): 1691–1696.
- SH Jain, BW Powers, JB Hawkins & JS Brownstein (2015). The digital phenotype. *Nat Biotech*, 33(5), 462–463.
- TR Insel (2017). Digital phenotyping: Technology for a new science of behavior. *JAMA*, 318(13), 1215–1216.



Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019). Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. NPJ digital medicine, 2(1), 9.



## **Biomarkers & Digital Biomarkers**

- · Biomarker [1]
  - a defined characteristic
  - that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions
  - e.g., blood pressure
- Digital biomarker [2]
  - a characteristic or set of characteristics
  - collected from digital health technologies,
  - that is measured as an **indicator** of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.
  - e.g., **location entropy** extracted from the phone's GPS as an early indicator of depression
  - e.g., cardiovascular features extracted from wearable devices to identify atrial fibrillation
- 1. U.S. Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Final guidance document.
- 2. Vasudevan, S., Saha, A., Tarver, M.E. *et al.* Digital biomarkers: Convergence of digital health technologies and biomarkers. *npj Digit. Med.* **5**, 36 (2022).




## Copenhagen Research Platform – CARP



Large-scale data science platform for digital phenotyping and mobile health technology

- Open-source programming framework
  - components & frameworks for the design of mHealth applications
  - used to create disease-specific solutions
  - developed and shared with research & industry partners (open source)
- "Out-of-the-Box" Study Hosting
  - CARP instance hosted @DTU Computerome (HPC)
  - GDPR compliant for Danish researchers
  - configurable study setup
  - standard participant phone app
  - large-scale analysis of data



carp.dk

## **CARP Components**



**CARP** Core

- domain model and standards



CARP Mobile Sensing (CAMS)

- mobile & wearable sensing framework



CARP Research Package

- informed consent & survey framework




**CARP** Cognition Package

- cognitive test framework incl. 14 pre-made tests



CARP Web Services (CAWS)

- cloud-based infrastructure for data management





#### **Data Collection**

#### **Physiological**

- weight, height, ...
- ECG, HR, HRV, blood pressure...
- Blood glucose

#### **Behavioral**

- physical activity (steps, movement, ...)
- social activity (communication, calendar, messaging, ...)
- phone usage (screen, connectivity, ...)

#### Contextual

- location (geo-position, geofence, ...)
- weather, air quality

#### **Patient-Reported**

- surveys
- ecological momentary assessments (EMA)
- audio & video

#### Cognition

- 8 Neurocognitive domains
- 14 validated gold-standard cognitive tests




## **Plug-in Model for Devices**

- Movisens (activity, ECG, EDA)
- Nokia Bell Labs eSense (noise, activity)
- Polar Sense & H10 (HR/ECG)
- Empatica E4 (HR, GSR, activity)
- Dexcom (CGM)
- Apple Health
- Google Health Connect
- Dexcom (CGM)
- Garmin (activity, sleep, HR, ...)
- Fitbit (activity, sleep, HR, BP, ECG, weight,
- Withings (activity, sleep, HR, BP, ECG, weight, ...)




















## Patient Reported Data (PRO)

- Informed Consent
- Questionnaires / Surveys
- Ecological Momentary Assessment (EMA)
- Image Capture
- Audio Recording
- Video Recording



## Cognition

- 14 validated gold-standard cognitive tests
- 8 Neurocognitive domains
  - Sensation
  - Perception
  - Motor skills and construction
  - Attention and concentration
  - Memory
  - Executive functioning
  - Processing speed
  - Language and verbal skills




Picture Sequence Memory



Multiple Object Tracking





Visual Array Change



## "CARP Studies" App (standard, out-of-the box)

- Triggering of user tasks
  - surveys, cognitive tests, EMAs, ...
  - notifications
- Sensor data collection
  - on-board mobile sensing
  - wearable devices
- Informed Consent (eConsent)
- On-going study information
- Internationalization (DA, EN, ES, FR, ...)
- Cross-platform (Android & iOS)
- Infrastructure-independent (upload data to any backend server)
- Available in Apple & Google App Stores











## **Clinical Outcome Assessment / Digital Biomarker**









## **Clinical Outcome Assessment / Digital Biomarker**

Concept being measured	Type of measure
Tasking a study participant to complete a structured tapping exercise on the smart phone for measuring ocation of the tap and time delays between taps for identifying signal for an early sign of a neurological disorder	Digital biomarker
Tasking a study participant to complete a structured tapping exercise on the smart phone for measuring the Study participant's functional ability	e COA – Performance outcome
Physical function questionnaire that asks a study participant about hand-related activities of daily living	COA – Patient-reported outcome
Clinician observing a study participant complete a hand exercise and grading the participant's performance	e COA – Cimician-reported outcome
ife partner reporting observations of spouse doing certain hand-related functions	COA – Observer-reported outcom

Vasudevan, S., Saha, A., Tarver, M.E. *et al.* Digital biomarkers: Convergence of digital health technologies and biomarkers. *npj Digit. Med.* **5**, 36 (2022).



## Digital Phenotyping in Neuroscience

- **#1** MONARCA Digital Biomarkers in Bipolar Disorder
- **#2 ICAT** Internet-based Cognitive Assessment
- **#3** Neuropathy Tracker Assessment of Neuropathy





## **Digital Phenotyping in Neuroscience**

- **#1** MONARCA Digital Biomarkers in Bipolar Disorder
- #2 ICAT Internet-based Cognitive Assessment
- **#3** Neuropathy Tracker Assessment of Neuropathy



## **MONARCA** Project

DTU

- Bipolar disorder (manio-depressive)
- EU STREP project | **2010**-2014 | 13 partners
- Copenhagen team
  - Psychiatric Center Copenhagen (RegionH)
  - IT University of Copenhagen
- MONARCA system
  - Self-assessment mood | sleep | stress | medicine | ...
  - Auto-assessment physical activity | mobility | social activity | phone usage
  - Feedback visualizations | medication | actions-to-take | triggers | earlywarning-signs | impact factors
  - Mood forecast predict mood for next 5 days



Bardram, J. E., Frost, M., Szántó, K., Faurholt-Jepsen, M., Vinberg, M., & Kessing, L. V. (2013, April). Designing mobile health technology for bipolar disorder: a field trial of the MONARCA system. In *Proceedings of the SIGCHI conference on human factors in computing systems* (pp. 2627-2636).





#### Clinical Validation

#### Clinical STUDY

- N=61 | 6 m | 19 m
- HDRS-17 (depression) and YMRS (manic)

- YMRS

   significant correlation "Smartphones provide an and could serve as and manifer to monitor illness arker with bipolar disorder."

   significant correlation "Smartphones biomarks with bipolar and YMRS presented to monitor biomarks with bipolar and YMRS presented to monitor in patients with bipolar and YMRS presented to monitor biomarks with bipolar and YMRS presented to monitor bipolar and YMRS presente

Table 2. Correlations between self-monitored data<sup>a</sup> collected using smartphones and depressive and manic symptoms measured using the HDRS-17 and YMRS, respectively<sup>b</sup>

	Unadjusted			Adjusted <sup>c</sup>			
	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value	
Mood (scale: -3 to +3)							
HDRS-17	-0.055	-0.067 to -0.042	< 0.001	-0.058	-0.071 to -0.045	<0.001	
HDRS-17 sub-item 1 (mood)	-0.38	-0.45 to -0.30	< 0.001	-0.38	-0.46 to -0.31	< 0.001	
YMRS	0.39	0.016-0.062	< 0.001	0.039	0.017-0.062	<0.001	
YMRS sub-item 1 (mood)	0,38	0.24-0.53	< 0.001	0.38	0.24-0.53	<0,001	
Sleep (hours/night)					'		
HDRS-17	-0.017	-0.048 to 0.014	0.28	-0.02	-0.052 to 0.011	0.21	
YMRS	-0.047	-0.088 to -0.005	0.027	-0.047	-0.088 to -0.006	0.026	
A0112	1						
A WO	-0.037	-0.053 to -0.020	< 0.001	-0.042	-0.059 to -0.025	< 0.001	
tive Way	0.047	0.022-0.072	< 0.001	0.048	0.023-0.072	< 0.001	
L1 - N							
carr	047	0.029-0.065	<0.001	0.046	0.027-0.064	< 0.001	
as an	12	-0.013 to 0.033	0.34	0.012	-0.013 to 0.037	0.35	
anic	<b>—</b>						

milton Depression Rating Scale-17 item; YMRS = Young Mania Rating Scale. analyzed for the current day and three days before ratings with the HDRS-17 and YMRS, as

Table 5. Correlations between automatically generated objective data a collected using smartphones and affective states according to the HDRS-17 and YMRS presented as categorical data b, respectively

	Unadjusted			Adjusted <sup>d</sup>		
	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value
Incoming calls (no./day)						
Asymptomatic versus mania	0.95	0.076-1.82	0.033	0.97	0.10-1.84	0.029
Duration incoming calls (sec/day)						
Asymptomatic versus hypomania	729.51	334.87-1124.13	< 0.001	768.10	374,34-1161,86	<0.001
Outgoing calls (no./day)						
Asymptomatic versus hypomania	2.09	0.38-3.80	0.016	2.08	0.37-3.80	0.017
Duration outgoing calls (sec/day)						
Asymptomatic versus moderate to severe depression	452.17	149.56-754.78	0.003	421.57	111.55-731.60	0.008
Asymptomatic versus hypomania	623.15	173.63-1072.67	0.007	641.53	190.41-1092.65	0.005
Outgoing text messages (no /day)						
Asymptomatic versus mania	4.14	-0.38 to 8.67	0.073	4.42	-0.10 to 8.95	0.055

CI = confidence interval; HDRS-17 = Hamilton Depression Rating Scale-17 item; YMRS = Young Mania Rating Scale

M Faurholt-Jepsen, M Vinberg, M Frost, EM Christensen, JE Bardram, LV Kessing. Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar Disorders, 17(1): 2015

<sup>&</sup>lt;sup>a</sup>Averages of the smartphone data were analyzed for the current day and three days before ratings with the HDRS-17 and YMRS, as these rating scales address symptoms over the last four days.

bScores on the HDRS-17 or YMRS ≤ 7 were defined as asymptomatic. Scores on the HDRS-17 or YMRS from 7 to 14 were defined as mild depression or hypomania. Scores on the HDRS-17 or YMRS > 14 were defined as moderate to severe depression or mania.

<sup>&</sup>lt;sup>c</sup>Analyses including all study participants; total N = 61,

dAdjusted for age and sex.



## Classification Affective Disorders from Mobility Patterns

- Classification of affective disorders based on mobility patterns
  - bipolar disorder (mania-depression)
  - unipolar disorder (c
- T = 6 months
- N = 65 (BD) | N =
- Mobility Features
  - no. stops
  - duration stops

  - location entropy

depression)	rived f	1
	erns derived formising digital omising between parties of the state of	
wiity patr	omising dignary	1
Mopilies & br	a between	U
data are ininatir	19 1	a
discrim	de	ef

Table 3	bile 1	ocatio	n er i	Cont	of Affective Disorders sents lists available a
Table 3 Classic M MG Aldiagra Atients W Euthymic state	nostic	marr and	UD PPV <sup>d</sup>	NPV <sup>e</sup>	BD) vers collecte
i ents V	vitti	0.65 (0.03)	0.70 (0.02)	0.64 (0.03)	0.75 (0.02)
vs. BD, euthymic state	0.78 (0.04)	0.65 (0.06)	0.81 (0.03)	0.61 (0.05)	0.79 (0.04)
UD, depressive state vs. BD, depressive state	0.70 (0.07)	0.77 (0.07)	0.68 (0.06)	0.78 (0.05)	0.79 (0.05)

efined as smartphone-based self-assessed mood < 1 and >-1; a depressive state was defined as smartphone-based self-assessed mood  $\leq -1$ .

- <sup>b</sup> Sensitivity = true positive / positive.
- <sup>c</sup> Specificity = true negative / negative.
- <sup>d</sup> Positive predictive value.
- e Negative predictive value.
- f Area under the curve.

ing author at: Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Blegdamsvel 9, DR-2100 Copenhagen

mal of Affective Disorders

arning models in r disorder

> ared with patients with UD, patients with BD 7), and an AUC of 0.79 (SD 0.03)

helpful for clinicians to add a supplementary

ng the current state of illness.

Received 12 November 2021; Received in revised form 10 January 2022; Accepted 18 March 2022

M Faurholt-Jepsen, J Busk, DA Rohani, M Frost, M Tønning, JE Bardram, LV Kessing (2022). Differences in mobility patterns according to machine learning models in patients with bipolar disorder and patients with unipolar disorder. Journal of Affective Disorders, 306, 246-253



## Classification – Voice & Mood (2016 & 2021)

Collection of voice features in naturalistic setting

- (emolarge)

- -depressive state: 750/ The pressive state: 700/ "Voice represent a supplemental BD from a state and represent a supplemental BD."

The pressive state and a state marker within BD."

The pressive state and a state marker within BD."

The pressive state and a state marker within BD."

The pressive state and a state marker within BD."

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state and a state marker within BD.

The pressive state marker within BD.

The pressive state marker within BD.

The pres ...anic state: 75% (0 objective marker marker within BD).

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 79% HC and a state marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 objective marker within BD.

- HC vs. bipolar: 75% (0 ob


disorder. Transl Psychiatry. Macmillan Publishers Limited.

Psychiatric Center Copenhagen, Rigahospitale Laboratory, IT University of Copenhagen, Cop 2100 Copenhagen, Denmark, E-mail: mariosrlounfolt-jopsen.dk Received 25 January 2016; proised 4 April 201 M Faurholt-Jepsen, J Busk, M Frost, M Vinberg, EM Christensen, O Winther, JE

M Faurholt-Jepsen, DA Rohani, J Busk, M Vinberg, JE Bardram, LV Kessing (2021). Voice analyses using smartphone-based data in patients with bipolar disorder,

Bardram, LV Kessing (2016,). Voice analysis as an objective state marker in bipolar

unaffected relatives and healthy control individuals, and during different affective states. International Journal of Bipolar Disorders, 9, 1-13.



Technical University of Denmark



## **Digital Phenotyping in Neuroscience**

- **#1 MONARCA** Digital Biomarkers in Bipolar Disorder
- **#2 ICAT** Internet-based Cognitive Assessment
- **#3** Neuropathy Tracker Assessment of Neuropathy



# ICAT – Internet-based Cognitive Assessment Tool

SCREEN FOR COGNITIVE IMPAIRMENT IN PSYCHIATRY (SCIP)
Purdon, Ph.D., Clinical Professor of Psychiatry, University of Alberta; spurdon@ualberta.ca
© 2005 Purdon Neuropsychological Labs inc., Edmonton, Alberta, Canada

1. List Learning 1 presentation. For the 1 lawnt you to repeat bit at a pace of about 3 sec am going to read the limanty words as you ca

Received: 5 September 2017 Revised: 21 November 2017 Accepted: 15 December 2017

WILEY BIPOLAR DISORDE

 Based on the Screen for Cognitive Impairment (SCIP) in Psychiatry

- clinically administered
- paper-based & manual scoring

#### ICAT Vision

- patient self-administered
- large-scale deployment (national s
- useful across many health domain

#### ICAT Technology

- browser-based (scalable)
- automatic speech recognition & scoring
- study & participant management using CARP

Table 1. Descriptio	n of the internet-based cogr Task 1: list learning <sup>a</sup>	Task 2: consonant repe- tition <sup>b</sup>	Task 3: Wechsler Adult Intelligence Scale let- ter-number sequencing <sup>6</sup>	Task 4: delayed list learning <sup>d</sup>	Task 5: visuomotor tracking <sup>6</sup>
Measure	Verbal memory (imme- diate recall)	Working memory	Working memory	Delayed verbal memory (delayed recall)	Psychomotor speed
Scoring criteria	Total number of correct- ly recalled words for 3 trials	Total number of correct- ly recalled letters	Total number of correct- ly sorted sequences	Total number of correct- ly recalled words	Total number of correct matching letters
Score range	0-30	0-24	0-21	0-10	0-30
Practice test	No	No	Yes	No	Yes

VI.T. I= (\_\_-23.59)2.87, \\
14.26)/2.25. Global index is

184 | C 2018 John Wiley & Sont Aris.
Published by John Wiley & Sont Ltd

Weyorkind Branz you (ill) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,


Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,


Weleyorkind Branz Zeon (ill) and the screen cognition in partially or fully remitted patients whenever possible, (II) use brief,

Hafiz, P., Miskowiak, K. W., Kessing, L. V., Jespersen, A. E., Obenhausen, K., Gulyas, L., ... & Bardram, J. E. (2019). The internet-based cognitive assessment tool: system design and feasibility study. *JMIR formative research*, 3(3).



- in-clinic assessment
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based tool for cognition
- validation | spe\_"ICAT is a [...] valid web-based cognition screening tool [...] - Results
- scores: ρ = 0.72, [...] a novel web-based cognition management of bipolar aspeech: ρ = 0.91, for large-scale assessment (significant management) cognition in the clinical management (significant management) (

120 110



his means that it is not necessarily the tive difficulties who display largest

209

176

159

123

173 241

Maler

98.00

Miskowiak, K. W., Jespersen, A. E., Obenhausen, K., Hafiz, P., Hestbæk, E., Gulyas, L., ... & Bardram, J. E. (2021). Internet-based cognitive assessment tool: sensitivity and validity of a new online cognition screening tool for patients with bipolar disorder, Journal of Affective Disorders, 289, 125-134.



## **Digital Phenotyping in Neuroscience**

- **#1** MONARCA Digital Biomarkers in Bipolar Disorder
- #2 ICAT Internet-based Cognitive Assessment
- **#3** Neuropathy Tracker Assessment of Neuropathy



## **Neuropathy Tracker**

#### Peripheral neuropathy

- common complication of diabetes or cancer treatment
- early detection and treatment are crucial
- done in the clinic using paper-and-pen tool(s)

#### Vision

- patient-administered, "at-home" assessment
- screening | diagnosis | treatment monitoring
- early detection

#### Technology

- "Custom" designed and implemented using the CARP software components
- Using patients' own phones and accessories

User Interface Pati Stu Examination Visi Main Page Settings Completed Mo Detailed Examination Pickers & Results Steps Dialogs Neuropathy Tests Neuropathy Util Localization Sections Score Settings Calculation Repository Steps Result Result Export Repository Research Package Result Survey Localization Flutter Plugins shared vibration serializable preferences sembast to\_csv Operating System File System Vibration Fig 7. Software architecture. Software architecture diagram of the Neuropathy Tracker comprising of (i) UI components (red) as shown in Figs 3 to 6: (ii) business logic components (green); (iii) Research Package (RP) components (orange); (iv) Flutter plugins (blue), and (v) the phone's operating system services (yellow).

Bardram, J. E., Westermann, M., Makulec, J. G., & Ballegaard, M. (2025). The Neuropathy Tracker—A mobile health application for ambulatory and self-administred assessment of neuropathy. *PLOS Digital Health*, 4(2).



## **User-Centered Design**

involving neurologists, patients, and healthy subjects

ensuring a high degree of clinical validity and usability

Settings Page Home Page Results Page 10000 - Examination Pages The place of the control of the College College **Information** plus soldie organisations in per tip or bell The description is a ball of Georgia meriority passifiche and basis is Exemples of byhademic as manual risk territoria, para in affect entrante de la sentencia Her believing will be RECEIVED IN HOSP BY year symplectic and facings . Therape sample to have Butting that assumination (this pitch on your feet and upon. stightic and the love, for example by taking int personal factor of the same

Bardram, J. E., Westermann, M., Makulec, J. G., & Ballegaard, M. (2025). The Neuropathy Tracker—A mobile health application for ambulatory and self-administred assessment of neuropathy. *PLOS Digital Health*, 4(2).



Mean Difference: 4.24 Upper LoA: 17.19 Lower LoA: -8.72 Mean ± 1 SD

## **Feasibility Study**

Results

- p = 0.86, p < 0.0

- Bland-Altman Plo

- Results

- p = 0.86, p < 0.0

- Bland-Altman Plo

- Results

- p = 0.86, p < 0.0

- Bland-Altman Plo

- Results

- p = 0.86, p < 0.0

- Bland-Altman Plo

- Results

- p = 0.86, p < 0.0

- Bland-Altman Plo

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results


- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0.0

- Results

- p = 0.86, p < 0



(2025). The Neuropathy Tracker—A mobile health application for ambulatory and self-administred assessment of neuropathy. PLOS Digital Health, 4(2),

Bardram, J. E., Westermann, M., Makulec, J. G., & Ballegaard, M.

Fig 10. Concurrent validity. A Bland-Altman plot with the differences between the Neuropathy Tracker ("App") and TNSc measures on the y-axis and their means on the x-axis. The plot includes horizontal lines for the mean difference and the limits of agreement (LoA) and is color-coded by sex (green = male, blue = female)



## **Digital Phenotyping in Neuroscience**

- **#1** MONARCA Digital Biomarkers in Bipolar Disorder
- **#2 ICAT** Internet-based Cognitive Assessment
- **#3** Neuropathy Tracker Assessment of Neuropathy



# DE Carp

Interested in **Digital Phenotyping** and using CARP as part of a research project?

Just reach out...



#### **Questions?**

Funding Acknowledgement



Innovationsfonden

novo nordisk **fonden** 

Bagger-Sørensen Fonden



Technical University of Denmark (c) Jakob E. Bardram – www.bardram.net